References
- National Survey on Drug Use and Health [Internet]. 2020. [cited September 9,2020]. Available from: https://www.datafiles.samhsa.gov/study-series/national-survey-drug-use-and-health-nsduh-nid13517.
- Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. JAMA. 2017;317(9):967–8. doi:https://doi.org/10.1001/jama.2017.0001.
- Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230–S42. doi:https://doi.org/10.1016/j.amepre.2017.12.022.
- Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70(2):S13–S27. doi:https://doi.org/10.1016/S0376-8716(03)00056-5.
- US Department of Health and Human Services. 86 FR 22439: Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. Washington, DC; 2021.
- Dabrowska VRG A, Sacco LN, Yeh BT. The SUPPORT for Patients and Communities Act (P.L. 115-271): Food and Drug Administration and Controlled Substance Provisions (No. R45405). Washington, DC; 2018.
- Dick AW, Pacula RL, Gordon AJ, Sorbero M, Burns RM, Leslie D, Stein BD. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002–11. Health Aff (Millwood). 2015;34(6):1028–34. doi:https://doi.org/10.1377/hlthaff.2014.1205.
- Ghertner R. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018. Drug Alcohol Depend. 2019;204:107527. doi:https://doi.org/10.1016/j.drugalcdep.2019.06.029.
- Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–6. doi:https://doi.org/10.1370/afm.1735.
- Langabeer JR, Stotts AL, Cortez A, Tortolero G, Champagne-Langabeer T. Geographic proximity to buprenorphine treatment providers in the U.S. Drug Alcohol Depend. 2020;213:108131. doi:https://doi.org/10.1016/j.drugalcdep.2020.108131.
- Drake C, Donohue JM, Nagy D, Mair C, Kraemer KL, Wallace DJ. Geographic access to buprenorphine prescribers for patients who use public transit. J Subst Abuse Treat. 2020;117:108093. doi:https://doi.org/10.1016/j.jsat.2020.108093.
- Flavin L, Malowney M, Patel NA, Alpert MD, Cheng E, Noy G, Samuelson S, Sreshta N, Boyd JW. Availability of buprenorphine treatment in the 10 states with the highest drug overdose death rates in the United States. J Psychiatr Pract. 2020;26(1):17–22. doi:https://doi.org/10.1097/PRA.0000000000000437.
- Jones CW, Christman Z, Smith CM, Safferman MR, Salzman M, Baston K, Haroz R. Comparison between buprenorphine provider availability and opioid deaths among US counties. J Subst Abuse Treat. 2018;93:19–25. doi:https://doi.org/10.1016/j.jsat.2018.07.008.
- Spetz J, Toretsky C, Chapman S, Phoenix B, Tierney M. Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions. JAMA. 2019;321(14):1407–8. doi:https://doi.org/10.1001/jama.2019.0834.
- Administration DE. Title 21 United States Code (USC) Controlled Substances Act. 2010.
- Knudsen HK, Lin LA, Lofwall MR. Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: a state-level longitudinal analysis. Subst Abus. 2020;41(2):259–68. doi:https://doi.org/10.1080/08897077.2019.1635959.
- Knudsen HK, Studts JL. Physicians as mediators of health policy: acceptance of Medicaid in the context of buprenorphine treatment. J Behav Health Serv Res. 2019;46(1):151–63. doi:https://doi.org/10.1007/s11414-018-9629-4.
- DEA REGISTRATION RECORD LAYOUT [Internet]. 2019. Available from: https://dea.ntis.gov/recordlayout.pdf.
- Substance Abuse and Mental Health Services Administration. Buprenorphine Practitioner Locator 2021. Available from: https://www.samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator.
- Beetham T, Saloner B, Wakeman SE, Gaye M, Barnett ML. Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study. Ann Intern Med. 2019;171(1):1–9. doi:https://doi.org/10.7326/M18-3457.
- Ghertner R, Ali MM. Increases in providers with buprenorphine waivers in the United States From 2016 to 2019. Psychiatr Serv. 2020;71(9):971. doi:https://doi.org/10.1176/appi.ps.201900635.
- Quest TL, Merrill JO, Roll J, Saxon AJ, Rosenblatt RA. Buprenorphine therapy for opioid addiction in rural Washington: the experience of the early adopters. J Opioid Manag. 2012;8(1):29–38.
- Stein BD, Gordon AJ, Dick AW, Burns RM, Pacula RL, Farmer CM, Leslie DL, Sorbero M. Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat. 2015;48(1):104–11. doi:https://doi.org/10.1016/j.jsat.2014.07.010.
- Huskamp HA, Busch AB, Souza J, Uscher-Pines L, Rose S, Wilcock A, Landon BE, Mehrotra A. How is telemedicine being used in opioid and other substance use disorder treatment? Health Aff (Millwood). 2018;37(12):1940–7. doi:https://doi.org/10.1377/hlthaff.2018.05134.
- Bunting AM, Oser CB, Staton M, Eddens KS, Knudsen H. Clinician identified barriers to treatment for individuals in Appalachia with opioid use disorder following release from prison: a social ecological approach. Addict Sci Clin Pract. 2018;13(1):23. doi:https://doi.org/10.1186/s13722-018-0124-2.
- Saunders JB, Jarlenski MP, Levy R, Kozhimannil KB. Federal and state policy efforts to address maternal opioid misuse: gaps and challenges. Womens Health Issues. 2018;28(2):130–6. doi:https://doi.org/10.1016/j.whi.2017.10.011.